Skip to content

Endoscopic Assessment and Prediction of Microbiome-modifying Interventions

Endoscopic Assessment and Prediction of Microbiome-modifying Interventions

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03218579
Acronym
microbiome
Enrollment
45
Registered
2017-07-14
Start date
2013-02-01
Completion date
2020-12-30
Last updated
2017-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gut Microbiome, Antibiotic Side Effect

Keywords

microbiome, intestinal bacteria

Brief summary

The investigators would like to examine the extent of gut microbiome rehabilitation in healthy people after the consumption of antibiotics. Outcomes of probiotic treatment versus bacteriotherapy will be compared.

Detailed description

The investigators would like to examine the extent of rehabilitation of the composition and functioning of the intestinal bacteria in healthy people after the consumption of antibiotics. Since the digestive mocus enables the connection between the host and the bacteria that live within it, the investigators would like to characterize the microbiome in the different areas along the digestive system - before antibiotic treatment and after rehabilitation by probiotic treatment versus bacteriotherapy.

Interventions

DIETARY_SUPPLEMENTProbiotic treatment

4 weeks of probiotic treatment after 7 days of antibiotics (Metronidazole+Ciprofloxacin)

BIOLOGICALBacteriotherapy

Bacteriotherapy (autologous fecal microbiota transplantation) after 7 days of antibiotics (Metronidazole+Ciprofloxacin)

Sponsors

Weizmann Institute of Science
CollaboratorOTHER
Tel-Aviv Sourasky Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteers * Age: 18 years and up * Gender: women and men

Exclusion criteria

* Pregnancy * Age under 18 years * antibiotic treatment 3 months prior to enrollment * Viral Hepatitis * HIV positive

Design outcomes

Primary

MeasureTime frameDescription
Microbiome composition1 yearstool samples

Secondary

MeasureTime frameDescription
Microbiome composition1 monthGastrointestinal tract biopsies

Countries

Israel

Contacts

Primary ContactNoya Horowitz, PhD
noyah@tlvmc.gov.il97236974297

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026